19381019 |
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J,
Du, X,
Chen, Y,
Chan, P,
Li, H,
Wu, P,
Marsters, S,
Stawicki, S,
Tien, J,
Totpal, K,
Ross, S,
Stinson, S,
Dornan, D,
French, D,
Wang, QR,
Stephan, JP,
Wu, Y,
Wiesmann, C,
Ashkenazi, A
|
J Clin Invest |
2009 |
20439987 |
NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells
Krejci, P,
Murakami, S,
Prochazkova, J,
Trantirek, L,
Chlebova, K,
Ouyang, Z,
Aklian, A,
Smutny, J,
Bryja, V,
Kozubik, A,
Wilcox, WR
|
J Biol Chem |
2010 |
15029211 |
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
Grand, EK,
Chase, AJ,
Heath, C,
Rahemtulla, A,
Cross, NC
|
Leukemia |
2004 |
11290605 |
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells
Li, Z,
Zhu, YX,
Plowright, EE,
Bergsagel, PL,
Chesi, M,
Patterson, B,
Hawley, TS,
Hawley, RG,
Stewart, AK
|
Blood |
2001 |
16467200 |
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S,
Stewart, AK,
Rom, E,
Wei, E,
Li, ZH,
Kotzer, S,
Chumakov, I,
Singer, Y,
Chang, H,
Liang, SB,
Yayon, A
|
Blood |
2006 |
11429702 |
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
Ronchetti, D,
Greco, A,
Compasso, S,
Colombo, G,
Dell'Era, P,
Otsuki, T,
Lombardi, L,
Neri, A
|
Oncogene |
2001 |
11157491 |
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
Chesi, M,
Brents, LA,
Ely, SA,
Bais, C,
Robbiani, DF,
Mesri, EA,
Kuehl, WM,
Bergsagel, PL
|
Blood |
2001 |